Another quarter that Cramer found intriguing was HP, the slow-growth maker of printers and personal computers that broke off of Hewlett Packard in October.
Ordinarily Cramer wouldn't be magnetized by a legacy hardware business, but when HP reported a few weeks ago, the stock surged 7 percent in response.
"Judging by the action in the stock, you would think that HP shot the lights out, delivering a really good quarter," Cramer said.
But was it actually good?
When Cramer listened to the conference call, he found that HP told a much more conflicted story. Based on the fundamentals, Cramer determined that HP did not report a good quarter. The company is actually in secular decline, and it is unclear how it plans to turn things around.
Sometimes Cramer likes to go off the tape to look at privately held companies that could be a disruptor for their industry and lead the way for publicly held companies.
Back to the Roots is a private company founded by Nikhil Arora and Alejandro Velez. With no knowledge of the food industry, they founded the company in a frat house in 2009 and decided to change what goes into food and the way we think about it.
At first, they sold grow-your-own mushroom kits and have since expanded to sell food at the grocery store, including organic non-GMO breakfast cereal.
Back to the Roots is on a mission to "undo food" and take food out of a lab, to create trust and transparency behind the process. This allows consumers know what is in the food and going into their body.
"I think everyone is realizing that the pendulum has swung too far. We have been disconnected from our food, and it's got to come back and it's almost like we are entering this third wave about radical transparency," Arora said.
In the Lightning Round, Cramer gave his take on a few caller favorite stocks:
Calpine: "I don't like the power generation business. It's just too up and down. That's why I like AEP, and my charitable trust owns that one."
Synergy Pharmaceuticals: "It's down a lot, I'm not recommending any of the speculatives right now. I'm just not, they are losing people too much money. Why don't you just buy a Celgene? Celgene is doing quite well."